Cite
Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
MLA
Scott A. Laurie, et al. “Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC).” International Journal of Radiation Oncology*Biology*Physics, vol. 90, Nov. 2014, p. S2. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6569aa4847fc3607dd0b94e04e69af99&authtype=sso&custid=ns315887.
APA
Scott A. Laurie, Laura Q.M. Chow, Allen C. Chen, Yun Shen, Frances A. Shepherd, Rosalyn A. Juergens, Hossein Borghaei, David E. Gerber, Christopher T. Harbison, Jonathan H. Goldman, Naiyer A. Rizvi, Scott J. Antonia, Scott N. Gettinger, & Julie R. Brahmer. (2014). Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics, 90, S2.
Chicago
Scott A. Laurie, Laura Q.M. Chow, Allen C. Chen, Yun Shen, Frances A. Shepherd, Rosalyn A. Juergens, Hossein Borghaei, et al. 2014. “Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC).” International Journal of Radiation Oncology*Biology*Physics 90 (November): S2. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6569aa4847fc3607dd0b94e04e69af99&authtype=sso&custid=ns315887.